eMedicine Specialties > Pediatrics: General Medicine > Dermatology

Nevoid Basal Cell Carcinoma Syndrome

Benjamin Barankin, MD, FRCPC, Dermatologist, Private Practice, Toronto
Gary Goldenberg, MD, Assistant Professor of Dermatology, Director Dermatopathology Laboratory, University of Maryland School of Medicine; Gordon E Searles, OD, MD, FRCPC, FACP, Program Director, Clinical Assistant Professor, Department of Medicine, Division of Dermatology and Cutaneous Sciences, University of Alberta Hospital, Edmonton, Canada

Updated: Mar 13, 2009

Introduction

Background

Nevoid basal cell carcinoma syndrome (NBCCS) is an autosomal dominant disorder characterized by a predisposition to cancer and multiple developmental defects.¹ First reported in 1894 by Jarisch and White, it was first delineated in the 1950s and 1960s by Gorlin and Goltz. Individuals with nevoid basal cell carcinoma syndrome are predisposed to basal cell carcinomas (BCCs) of the skin, medulloblastomas, and ovarian fibromas; frequency of fibrosarcomas, meningiomas, rhabdomyosarcomas, and cardiac fibromas may also be increased. Nevoid basal cell carcinoma syndrome is unique to most hereditary disorders associated with cancer in that it features developmental defects.

Pathophysiology

Nevoid basal cell carcinoma syndrome chromosomal mutation has been mapped to bands 9q22.3, 9q31, and 1p32, where it acts as a tumor suppressor gene.² The degree of penetrance is high (approximately 97%), and, although the extent of expression of features often varies, severity tends to breed true within families. A mutation is present in the PTCH gene, the human homologue of the Drosophila patched gene. Inactivation of this gene is associated with development of BCCs and other tumors, as well as developmental errors.

Approximately 35-50% of cases represent new mutations. A 2-hit hypothesis is postulated, wherein an initial mutation in the germline of patients with nevoid basal cell carcinoma syndrome occurs, followed by a separate hit to the second allele, which is required to develop tumors in particular tissues. Additional genetic and environmental events may be required for full expression of the syndrome. Study results on chromosome instability and cellular radiation sensitivity in nevoid basal cell carcinoma syndrome have been conflicting and inconclusive.

Frequency

International

The prevalence of nevoid basal cell carcinoma syndrome ranges from 1 case per 57,000 population in England to 1 case per 164,000 population in Australia.³ Approximately 1-2% of all medulloblastomas and 0.5% (or estimated 4500 in the United States) of all BCCs may be attributed to this syndrome. BCCs, jaw cysts, palmar pits, and macrocephaly occur at frequencies of 75-80%. Prevalence of medulloblastoma in nevoid basal cell carcinoma syndrome is 3-5%, with a male-to-female ratio of 3:1. It is considered rare in black persons, with fewer than 5% of cases reported in this population. Also, black persons have far fewer BCCs (possibly because of increased skin pigmentation) but do exhibit many of the other features of nevoid basal cell carcinoma syndrome.

Mortality/Morbidity

The specific mortality rate for nevoid basal cell carcinoma syndrome has yet to be determined.

BCCs are reported in approximately 76% of nevoid basal cell carcinoma syndrome cases; the face and back are most severely affected, followed by the chest and upper limbs. Development of BCCs can be extensive; the presence of 500 or more BCCs is not entirely uncommon in patients older than 30 years. Early death is rare but has been reported due to brain and lung invasion and even metastases from BCCs.

Jaw cysts are reported in 75% of cases, with operations necessary for symptomatic or cosmetic reasons. Although often asymptomatic, jaw cysts occasionally cause pain, swelling, abnormal taste sensation, and oral discharge.

Race

Medulloblastoma is considered rare in black persons; fewer than 5% of cases are reported in this population.⁴ Also, black persons have far fewer BCCs (possibly because of increased skin pigmentation) but do exhibit many of the other features of nevoid basal cell carcinoma syndrome.

Sex

Males and females are affected with equal frequency by nevoid basal cell carcinoma syndrome, but prevalence of medulloblastoma in nevoid basal cell carcinoma syndrome has a male-to-female ratio of 3:1.

Age

The average age for diagnosis of nevoid basal cell carcinoma syndrome is 13 years. The average age for presentation of BCC is 20 years.

Clinical

History

Patients with nevoid basal cell carcinoma syndrome (NBCCS) may be asymptomatic or may have symptoms of associated conditions. Patients may report a change in number and characteristics of nevi. A positive family history is often noted, with approximately one half of first-degree relatives of affected individuals showing signs of this syndrome.

Jaw cysts are often asymptomatic but may occasionally cause jaw swelling, pain, abnormal taste, or an oral discharge.

Physical

Along with benign and malignant tumors, patients may present with numerous malformations, including the following:

• Pits in the palms of the hands and the soles of the feet (60%)
  
  

  

  Palmar pits in an adult.

  
  
• Keratocysts of the jaw (80%, with a 30-60% recurrence rate)
• Cleft palate
• Coarse characteristic facies with milia, frontal bossing, widened nasal bridge, and mandibular prognathia
• Strabismus, dystrophic canthorum, ocular hypertelorism, and congenital blindness
• Dysgenesis of the corpus callosum
• Calcification of the falx cerebri
• Spina bifida occulta, pectus deformity, and other spine abnormalities
• Bifid ribs and other rib abnormalities
• Ectopic calcification, mesenteric cysts
• High arched eyebrows and palates
• Narrow sloping shoulders
• Immobile thumbs
• Low-pitched voice in females
• Kidney anomalies
• Hypogonadism in males
• Macrocephaly and generalized overgrowth

Patients often are taller (proportionately) and occasionally exhibit features similar to acromegaly.

Pitting of the palms or soles is very specific for nevoid basal cell carcinoma syndrome, and, therefore, examination is useful and is often aided by soaking the hands in warm water for 10 minutes to increase visibility of pits. Pits are permanent, not palpable, and asymptomatic. They appear as shallow depressions, 1-3 mm in depth and 2-3 mm in diameter, caused by a partial or complete absence of stratum corneum. Occasionally present in childhood, they develop more often in the second decade of life. The number of pits increases with age and can total into the hundreds.

Performing a biopsy on skin tags in children is a recent suggestion because they may be early presenting signs of nevoid basal cell carcinoma syndrome.

Diagnosis may be difficult because of the variability this condition's expressivity and different ages of onset for various traits of this disorder. For instance, a medulloblastoma may develop in a patient aged 2 years, but jaw cysts and basal cell carcinomas (BCCs) may not develop until the patient is aged 15 years and 20 years, respectively.

BCCs occur in both sun-exposed skin and nonexposed skin. BCCs have been reported to develop in patients as young as 2 years old but appear more commonly in patients aged 17-35 years. BCCs vary in size from 1-10 mm in diameter and commonly involve the face, back, and chest. The number of BCCs can vary from a few to more than a thousand, but BCCs do not appear in all affected persons.

Approximately 10% of whites and 60% of blacks do not develop BCCs as part of the syndrome. Smaller nevoid BCCs tend to be flesh colored, whereas larger lesions are often pigmented with frequent ulceration. Although the presentation of BCCs is most often bilateral, cases of unilateral or even quadrant distribution have been reported. Most lesions remain static in growth, although after puberty, a small fraction of BCCs become aggressive, with local invasion. An increase in size, ulceration, bleeding, and crusting indicate an invasive process.

Most patients with nevoid basal cell carcinoma syndrome seek medical attention because of their BCCs or jaw cysts.

Jaw cysts are often multiple, with an average prevalence of 6 cysts and a range of 1-30 cysts. Roughly 80% of patients with nevoid basal cell carcinoma syndrome who are older than 20 years develop cysts. Cysts of the jaw are often located in the premolar area and may displace the child's teeth. They can be unilocular or multilocular with a preference for the mandible. Often multiple and bilateral, they can cause considerable symptoms, including pain, swelling, intraoral drainage, and unusual taste. One third of jaw cysts do not cause any symptoms. Jaw cysts may displace teeth, with resulting malocclusion, and they may cause pathologic fractures of the mandible or facial distortion.

The diagnosis of NBCCS depends on the presence of one of the following: 2 major features, 1 major feature and an affected first-degree relative, 2 minor features and an affected first-degree relative, or multiple BCCs in childhood. The major and minor features are as follows:

• Major features - Multiple BCCs or one appearing before age 20 years, odontogenic keratocysts confirmed by histology, palmar or plantar pits (>3), bilamellar calcification of the falx cerebri, positive family history of nevoid basal cell carcinoma syndrome
• Minor features - Congenital skeletal anomaly (ie, bifid ribs, vertebral anomalies), macrocephaly (>97th percentile with frontal bossing), cardiac or ovarian fibroma, medulloblastoma, lymphomesenteric cysts, congenital malformations (ie, cleft lip/palate, polydactyly, eye anomaly)

Causes

A defect in a tumor suppressor gene on chromosome band 9q23.1-q31 causes nevoid basal cell carcinoma syndrome. No clear evidence suggests chromosome instability or cellular radiation sensitivity.

Differential Diagnoses

Other Problems to Be Considered

Bazex syndrome
Linear unilateral basal cell nevus with comedones
Rasmussen syndrome
Rombo syndrome

Workup

Laboratory Studies

• No specific laboratory blood tests are required in the workup of nevoid basal cell carcinoma syndrome (NBCCS).
• Genetic testing is not widely available at this time. However, in research settings, genotyping is informative in identifying additional family members once the proband's genotype has been determined. Molecular genetic studies can be used to identify the mutation prenatally, postnatally, and preimplantationally. Definitive presymptomatic diagnosis can be achieved by molecular genetic linkage studies currently taking place at the Yale University School of Medicine.

Imaging Studies

• Radiography
  • Skull, neck, and chest radiography are useful in diagnosing the condition at birth in individuals at risk. Panoramic radiography of the jaw is used to diagnose jaw cysts. Hand and spinal column radiography may also be helpful.
  • Radiologic signs include calcification of the falx cerebri or tentorium cerebelli, bridged sella turcica, large paranasal sinuses, increased mandibular length, rib anomalies (eg, bifid, fused, missing, splayed), vertebral anomalies (eg, kyphoscoliosis, abnormal segmentation), short fourth metacarpal, sclerotic bone lesions (rare), and flame-shaped lucencies of the bones of the hand.
  • Because skeletal anomalies are a common and early presentation of the syndrome, occurrence of multiple lesions should raise suspicion of this syndrome because children may not yet manifest the other anomalies of nevoid basal cell carcinoma syndrome.
• CT scanning and MRI
  • Although radiography is often useful, CT scanning can be performed for earlier identification of the falx and tentorial calcification, cerebral atrophy, and dysgenesis or agenesis of the corpus callosum.
  • However, because of the radiation involved in CT scanning, annual MRI of the cerebrum is recommended in detection of medulloblastomas in children aged 8 years and younger.
• Echocardiography: Although rare, cardiac fibromas can be excluded in those at risk for nevoid basal cell carcinoma syndrome by obtaining periodic chest radiographs and echocardiograms starting at birth and subsequently obtained on the basis of clinical suspicion.
• Ultrasonography: Ultrasonography of the pelvic area can aid in the diagnosis of ovarian fibromas.

Procedures

• No procedures are specific to this syndrome.

Histologic Findings

• Basal cell carcinomas (BCCs) that are part of nevoid basal cell carcinoma syndrome cannot be differentiated from BCCs observed in patients without the syndrome. The solid and superficial types of BCCs are most common in this syndrome, with all other types of BCC observed less frequently.
  
  

  

  Basal cell carcinoma. Mixed nodular and micronodular growth pattern (low power).

  
  
  

  

  Basal cell carcinoma. Mixed nodular and micronodular growth pattern (high power).

  
  

• Odontogenic keratocysts should be proven by histology. They are lined by thin, corrugated, stratified squamous epithelium with varying degrees of keratinization and surrounded by a thick fibrous capsule.

Treatment

Medical Care

• Although radiation is sometimes used to treat basal cell carcinomas (BCCs) in other settings, it is not recommended in the setting of nevoid basal cell carcinoma syndrome (NBCCS) because patients tend to form new BCCs at sites of irradiation soon after exposure. Radiation is a common treatment for medulloblastomas and results in extensive and invasive BCCs in the radiation field. Thus, when possible, radiation therapy should be minimized or avoided because more invasive BCCs and other tumors may result following treatment.⁵
• Management of superficial multicentric BCCs without follicular involvement can be achieved through total body application of topical 0.1% tretinoin cream and 5% 5-fluorouracil (5-FU) twice daily. Lesions around the eyes are treated with 5-fluorouracil only. Patients should be examined every 3 months, and lesions that are growing or invading should be excised or curetted.
• Evidence has accumulated to support the use of topical imiquimod on superficial BCCs.^6,7,8 One study in patients with nevoid basal cell carcinoma syndrome showed clearance of BCCs after treatment for 6-8 weeks. Other types of BCC do not appear to respond as well. Occlusion does not appear to affect the response rate.
• Oral isotretinoin has shown some benefit.⁹ However, it is not approved by the US Food and Drug Administration (FDA) for use in nevoid basal cell carcinoma syndrome and carries risk of toxicity.
• In adults, photodynamic therapy (PDT) has been beneficial in the treatment of BCCs (topical and systemic), with an average of a 95% complete tumor response rate; PDT is not recommended in children because of a poorer response rate and scarring.

Surgical Care

• BCCs are treated with curettage/electrodesiccation, simple excision, or Mohs surgery, but, because of the frequency of lesions, patients are left with extensive scarring from surgical procedures.
• Recently, ultrapulse carbon dioxide laser has been demonstrated to be effective in the treatment of small BCCs in low-risk areas in patients with nevoid basal cell carcinoma syndrome.
• Odontogenic keratocysts require an average of 4 operations throughout a lifetime, although some individuals have experienced up to 28 surgical procedures. Odontogenic keratocysts must be aggressively treated to prevent a high recurrence rate of 6-60% and should be removed by experienced oral-maxillofacial surgeons or otolaryngologists.
• Medulloblastomas require surgery, radiation, and chemotherapy.

Consultations

• Geneticist
• Dermatologist
• Plastic surgeon
• Oral surgeon
• Neurosurgeon
• Ophthalmologist
• Radiation oncologist
• Dentist

Medication

Medications are used for symptomatic patients, usually as a temporary measure, while patients await definitive treatment. New medical options, such as topical imiquimod and 5-aminolevulinic acid (ALA) photodynamic therapy, have increased and improved the armamentarium.

Keratolytics

Management of superficial multicentric basal cell carcinomas (BCCs) without follicular involvement can be achieved through total body application of topical 0.1% tretinoin cream and 5% fluorouracil once daily. Lesions around the eyes are treated with 5-fluorouracil only. Oral isotretinoin and etretinate have shown some marginal benefit, but they are not FDA approved for treatment of nevoid basal cell carcinoma syndrome (NBCCS) and carry risk of toxicity. More recently, topical imiquimod has shown benefit, as has photodynamic therapy.

Tretinoin (Avita, Retin-A)

Inhibits microcomedo formation and eliminates lesions present. Makes keratinocytes in sebaceous follicles less adherent and easier to remove.

Dosing

Adult

0.01-0.1% applied topically qd

Pediatric

Apply as in adults

Interactions

Toxicity increases with coadministration of benzoyl peroxide, salicylic acid, and resorcinol; avoid topical sulfur, resorcinol, salicylic acid, other keratolytics, abrasives, astringents, spices, and lime

Contraindications

Documented hypersensitivity; use on open skin surfaces; internal use

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Photosensitivity may occur with excessive sunlight exposure; caution in eczema; do not apply to mucous membranes, mouth, and angles of nose

Fluorouracil (Efudex, Fluoroplex)

Used topically for the management of superficial BCCs. Interferes with DNA synthesis by blocking methylation of deoxyuridylic acid and inhibiting thymidylate synthetase and subsequently cell proliferation.

Dosing

Adult

Only the 5% strength is recommended; apply around eyes qd for 10-14 d q60d

Pediatric

Apply as in adults

Interactions

None reported

Contraindications

Documented hypersensitivity; potentially serious infections

Precautions

Pregnancy

X - Contraindicated; benefit does not outweigh risk

Precautions

Incidence of inflammatory reactions may occur with occlusive dressings; porous gauze dressing may be applied for cosmetic reasons without increase in reaction

Isotretinoin (Accutane)

PO agent that treats serious dermatologic conditions. Synthetic 13-cis isomer of the naturally occurring tretinoin (trans -retinoic acid). Both agents are structurally related to vitamin A. Decreases sebaceous gland size and sebum production. May inhibit sebaceous gland differentiation and abnormal keratinization.
Until recently, only female patients of childbearing age needed to sign an informed consent form before initiating therapy. Because of heightened awareness of the potential of this product to cause depression and suicide, all patients are required to sign informed consent forms.

Dosing

Adult

1-2 mg/kg/d PO

Pediatric

0.5-1 mg/kg/d PO according to tolerance of dryness

Interactions

Toxicity may occur with vitamin A coadministration; pseudotumor cerebri or papilledema may occur when coadministered with tetracyclines; isotretinoin may reduce plasma levels of carbamazepine

Contraindications

Documented hypersensitivity; pregnancy or breastfeeding

Precautions

Pregnancy

X - Contraindicated; benefit does not outweigh risk

Precautions

May decrease night vision; inflammatory bowel disease may occur; may be associated with development of hepatitis; occasional exaggerated healing response of acne lesions (excessive granulation with crusting) may occur; patients with diabetes mellitus may experience problems in controlling blood sugar; avoid exposure to UV light or sunlight until tolerance achieved; discontinue treatment if rectal bleeding, abdominal pain, or severe diarrhea occur; caution in hypertriglyceridemia, hypercholesterolemia, depression, or bipolar illness

Acitretin (Soriatane)

Retinoic acid analog similar in action to etretinate or isotretinoin. Etretinate is the main metabolite and has demonstrated clinical effects similar to those observed with etretinate (removed from US market). Available as 10-mg and 25-mg cap.

Dosing

Adult

25 mg PO qd initially for 1 mo; titrate upward to 50 mg/d if tolerated

Pediatric

Not established; limited data suggest 0.3 mg/kg/d PO, round dose to the nearest cap combination

Interactions

Increases toxicity of methotrexate (avoid concomitant use); interferes with effects of microdose progestin (ie, minipill); coadministration with alcohol may enhance synthesis of etretinate, which has much longer half-life than acitretin (>120 d)

Contraindications

Documented hypersensitivity; pregnancy

Precautions

Pregnancy

X - Contraindicated; benefit does not outweigh risk

Precautions

Do not use in severe obesity; women of childbearing age must be capable of complying with effective contraceptive measures, continuing contraception is recommended for at least 3 y after stopping treatment with acitretin; etretinate may form from acitretin, which takes about 2-3 y to clear from the body; caution in impaired renal or liver function; perform AST, ALT, and LDH tests prior to initiation of acitretin therapy, at 1-wk to 2-wk intervals until stable, and thereafter at intervals as clinically indicated

Immune response modifiers

These agents regulate, adjust, or potentiate immune function.

Imiquimod cream (Aldara)

Induces secretion of interferon alpha and other cytokines. Mechanism of action is unknown.

Dosing

Adult

Apply topically 3 times/wk hs; leave on skin for 6-10 h

Pediatric

Not established

Interactions

None reported

Contraindications

Documented hypersensitivity

Precautions

Pregnancy

B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals

Precautions

Often causes local skin reactions (eg, erythema, edema, induration, vesicles, erosion, ulceration, excoriation, flaking, scabbing); other adverse effects may include itching, burning, and hypopigmentation

Photosensitizing Agent, Topical

These agents are used with photodynamic therapy.

Aminolevulinic acid (Levulan Kerastick)

Topical solution used to treat nonhyperkeratotic actinic keratoses on face or scalp. Treatment is 2-stage process. Solution is first applied to lesions, followed 14-18 h later by blue light illumination using BLU-U Blue Light Photodynamic Therapy Illuminator.
ALA is precursor of protoporphyrin IX (PpIX) in heme synthesis. PpIX is a photosensitizer and, when accumulation occurs, produces a photodynamic reaction. Light absorption results in excited state of porphyrin molecule and singlet oxygen generation, which further reacts to form superoxide and hydroxyl radicals.

Dosing

Adult

Apply solution to lesions, dabbing gently with wet applicator tip to uniformly wet lesion surface, including edges, without excess running or dripping; following approximately 1 h of application, use blue light, intense pulse light, or pulse-dye laser to activate

Pediatric

Not established

Interactions

Coadministration with other drugs causing photosensitization (eg, griseofulvin, thiazide diuretics, sulfonylureas, phenothiazines, sulfonamides, tetracyclines) may increase photosensitization

Contraindications

Documented hypersensitivity; cutaneous photosensitivity at wavelengths of 400-450 nm; porphyria or known allergies to porphyrins

Precautions

Pregnancy

C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus

Precautions

Do not wash actinic keratoses following solution application and prior to phototherapy; protect affected areas from sunlight prior to phototherapy; reduce light exposure if stinging or burning occurs; may cause lesions to scale or crust, itching, hypopigmentation or hyperpigmentation, or erosion

Follow-up

Further Outpatient Care

• For children at risk for inheriting the gene for nevoid basal cell carcinoma syndrome (NBCCS) or those in whom the condition is already diagnosed, regular visits to a dermatologist (every 2-3 mo) are encouraged, particularly during adolescence. Along with physical examination for pitting and other minor features of nevoid basal cell carcinoma syndrome, radiologic evaluation with rib, spine, and skull radiographs to look for abnormalities are indicated, as well as a panoramic radiograph of the jaws once a year in patients aged 8 years and older (or earlier if the child is compliant).
• Any patient presenting at an unusually young age (<5 y) with a medulloblastoma should be screened for nevoid basal cell carcinoma syndrome. Conversely, patients diagnosed with nevoid basal cell carcinoma syndrome at a young age should be screened for the presence of a medulloblastoma. Regular neurologic surveillance every 6 months with annual MRI of the cerebrum is indicated until children are aged 8 years.
• Most ovarian fibromas are asymptomatic and almost never become malignant. Initial ultrasonography performed at the preteen stage is advised, and ultrasonographic evaluation should be subsequently undertaken based on symptoms.
• Along with periocular basal cell carcinomas (BCCs), other ophthalmic manifestations include multiple eyelid cysts, strabismus, myopia, hyperopia, cataracts, and amblyopia. Thus, periodic ophthalmologic examination is warranted.¹⁰

Deterrence/Prevention

• Minimizing or avoiding ultraviolet radiation may lessen the risk of developing BCCs.

Complications

• Brain and lung invasion and even metastases from BCCs

Prognosis

• Early death from BCCs is rare but has been reported due to brain and lung invasion and even from metastases.
• In many cases of metastatic BCCs, early detection can identify solitary lesions that may be amenable to surgical removal. In situations where surgery is not feasible, radiotherapy offers a reasonable palliative option.

Patient Education

• Education on the importance of minimizing or avoiding ultraviolet radiation may lessen the risk of developing BCCs.
• For excellent patient education resources, visit eMedicine's Cancer and Tumors Center. Also, see eMedicine's patient education articles Skin Cancer and Skin Biopsy.

Miscellaneous

Medicolegal Pitfalls

• Failure to refer patients with odontogenic keratocysts to experienced oral-maxillofacial surgeons or otolaryngologists for aggressive treatment
• Failure to refer patients to a dermatologist when children are at risk for inheriting the gene for nevoid basal cell carcinoma syndrome (NBCCS) or for patients in whom the condition is already diagnosed
• Failure to educate the patient and/or parents on preventive measures (eg, avoiding ultraviolet radiation)
• Failure to use MRI instead of CT scanning in detection of medulloblastomas in children younger than 8 years because of the radiation involved in CT scanning
• Failure to minimize or avoid radiation therapy because more invasive basal cell carcinomas (BCCs) and other tumors result following treatment

Special Concerns

• In one series conducted by Shanley et al, more than 80% of patients with nevoid basal cell carcinoma syndrome could have been diagnosed within the first 2 decades of life without radiologic imaging.³

Multimedia

Media file 1: Palmar pits in an adult.

Media file 2: Syndactyly is noted in some affected persons such as this 8 year-old boy.

Media file 3: Basal cell carcinoma. Mixed nodular and micronodular growth pattern (low power).

Media file 4: Basal cell carcinoma. Mixed nodular and micronodular growth pattern (high power).

References

1. Lo Muzio L. Nevoid basal cell carcinoma syndrome (Gorlin syndrome). Orphanet J Rare Dis. Nov 25 2008;3:32. [Medline].

2. Yamamoto K, Yoshihashi H, Furuya N, et al. Further delineation of 9q22 deletion syndrome associated with basal cell nevus (Gorlin) syndrome: Report of two cases and review of the literature. Congenit Anom (Kyoto). Mar 2009;49(1):8-14. [Medline].

3. Shanley S, Ratcliffe J, Hockey A, et al. Nevoid basal cell carcinoma syndrome: review of 118 affected individuals. Am J Med Genet. Apr 15 1994;50(3):282-90. [Medline].

4. Hall J, Johnston KA, McPhillips JP, et al. Nevoid basal cell carcinoma syndrome in a black child. J Am Acad Dermatol. Feb 1998;38(2 Pt 2):363-5. [Medline].

5. Choudry Q, Patel HC, Gurusinghe NT, Evans DG. Radiation-induced brain tumours in nevoid basal cell carcinoma syndrome: implications for treatment and surveillance. Childs Nerv Syst. Sep 15 2006;[Medline].

6. Sterry W, Ruzicka T, Herrera E, et al. Imiquimod 5% cream for the treatment of superficial and nodular basal cell carcinoma: randomized studies comparing low-frequency dosing with and without occlusion. Br J Dermatol. Dec 2002;147(6):1227-36. [Medline].

7. Stockfleth E, Ulrich C, Hauschild A, et al. Successful treatment of basal cell carcinomas in a nevoid basal cell carcinoma syndrome with topical 5% imiquimod. Eur J Dermatol. 2002;12(6):569-72. [Medline].

8. van der Geer S, Ostertag JU, Krekels GA. Treatment of basal cell carcinomas in patients with nevoid basal cell carcinoma syndrome. J Eur Acad Dermatol Venereol. Dec 19 2008;[Medline].

9. Campbell RM, Digiovanna JJ. Skin cancer chemoprevention with systemic retinoids: an adjunct in the management of selected high-risk patients. Dermatol Ther. 2006;Sep-Oct;19(5):306-14. [Medline].

10. Taylor SF, Cook AE, Leatherbarrow B. Review of patients with basal cell nevus syndrome. Ophthal Plast Reconstr Surg. Jul-Aug 2006;22(4):259-65. [Medline].

11. Bale AE. The nevoid basal cell carcinoma syndrome: genetics and mechanism of carcinogenesis. Cancer Invest. 1997;15(2):180-6. [Medline].

12. Caccialanza M, Percivalle S, Piccinno R. Possibility of treating basal cell carcinomas of nevoid basal cell carcinoma syndrome with superficial x-ray therapy. Dermatology. 2004;208(1):60-3. [Medline].

13. Chiritescu E, Maloney ME. Acrochordons as a presenting sign of nevoid basal cell carcinoma syndrome. J Am Acad Dermatol. May 2001;44(5):789-94. [Medline].

14. Gorlin RJ. Nevoid basal cell carcinoma (Gorlin) syndrome. Genet Med. Nov-Dec 2004;6(6):530-9. [Medline].

15. Kimonis VE, Goldstein AM, Pastakia B, et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am J Med Genet. Mar 31 1997;69(3):299-308. [Medline].

16. Korczak JF, Brahim JS, DiGiovanna JJ, et al. Nevoid basal cell carcinoma syndrome with medulloblastoma in an African-American boy: a rare case illustrating gene-environment interaction. Am J Med Genet. Mar 31 1997;69(3):309-14. [Medline].

17. Manfredi M, Vescovi P, Bonanini M, Porter S. Nevoid basal cell carcinoma syndrome: a review of the literature. Int J Oral Maxillofac Surg. Mar 2004;33(2):117-24. [Medline].

18. Pastorino L, Cusano R, Baldo C, et al. Nevoid Basal Cell Carcinoma Syndrome in infants: improving diagnosis. Child Care Health Dev. May 2005;31(3):351-4. [Medline].

Keywords

nevoid basal cell carcinoma syndrome, NBCCS, Gorlin syndrome, basal cell nevus syndrome, BCNS, Gorlin-Goltz syndrome, multiple basal cell nevi, PTCH gene, basal cell carcinoma, BCC, medulloblastomas, ovarian fibromas, fibrosarcomas, rhabdomyosarcomas, meningiomas, cardiac fibromas, jaw cysts, palmar pits, macrocephaly, jaw swelling, keratocysts, cleft palate, spina bifida occulta, pectus deformity, spinal abnormalities, hypogonadism, kidney anomalies, acromegaly, malocclusion

Contributor Information and Disclosures

Author

Benjamin Barankin, MD, FRCPC, Dermatologist, Private Practice, Toronto
Benjamin Barankin, MD, FRCPC is a member of the following medical societies: American Academy of Dermatology, American Society for Dermatologic Surgery, Canadian Dermatology Association, Canadian Medical Association, International Society of Dermatology, Ontario Medical Association, Royal College of Physicians and Surgeons of Canada, and Women's Dermatologic Society
Disclosure: Nothing to disclose.

Coauthor(s)

Gary Goldenberg, MD, Assistant Professor of Dermatology, Director Dermatopathology Laboratory, University of Maryland School of Medicine
Gary Goldenberg, MD is a member of the following medical societies: American Academy of Dermatology and American Society of Dermatopathology
Disclosure: Graceway Pharmaceuticals LLC Consulting fee Consulting

Gordon E Searles, OD, MD, FRCPC, FACP, Program Director, Clinical Assistant Professor, Department of Medicine, Division of Dermatology and Cutaneous Sciences, University of Alberta Hospital, Edmonton, Canada
Gordon E Searles, OD, MD, FRCPC, FACP is a member of the following medical societies: Alberta Medical Association, American College of Physicians-American Society of Internal Medicine, Canadian Medical Association, College of Physicians and Surgeons of Alberta, Pacific Dermatologic Association, and Royal College of Physicians and Surgeons of Canada
Disclosure: Nothing to disclose.

Medical Editor

Kevin P Connelly, DO, Clinical Assistant Professor, Department of Pediatrics, Division of General Pediatrics and Emergency Care, Virginia Commonwealth University; Medical Director, Paws for Health Pet Visitation Program of the Richmond SPCA; Pediatric Emergency Physician, Emergency Consultants Inc, Chippenham Medical Center
Kevin P Connelly, DO is a member of the following medical societies: American Academy of Pediatrics, American College of Osteopathic Pediatricians, and American Osteopathic Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Robert A Schwartz, MD, MPH, Professor and Head, Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, UMDNJ-New Jersey Medical School
Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American College of Physicians, and Sigma Xi
Disclosure: Nothing to disclose.

CME Editor

Merrily P M Poth, MD, Professor, Department of Pediatrics and Neuroscience, Uniformed Services University of the Health Sciences
Merrily P M Poth, MD is a member of the following medical societies: American Academy of Pediatrics, Endocrine Society, and Lawson-Wilkins Pediatric Endocrine Society
Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD, Director, Department of Dermatology, Geisinger Medical Center
Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology
Disclosure: Nothing to disclose.

© 1994- by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)